Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells

Octavio Morante-Palacios1,2, Gerard Godoy-Tena1, Josep Calafell-Segura1, Laura Ciudad1, Eva M. Martínez-Cáceres3,4, José Luis Sardina5 and Esteban Ballestar1,2,6,*

1Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 08916, Badalona, Barcelona, Spain, 2Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Barcelona, Spain, 3Division of Immunology, Germans Trias i Pujol Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Barcelona, Spain, 4Department of Cell Biology, Physiology, Immunology, Autonomous University of Barcelona, 08193, Bellaterra, Barcelona, Spain, 5Epigenetic Control of Haematopoiesis Group, Josep Carreras Research Institute (IJC), 08916, Badalona, Barcelona, Spain and 6Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai 200241, China

Received June 22, 2022; Revised September 23, 2022; Editorial Decision October 06, 2022; Accepted October 10, 2022

ABSTRACT

Dendritic cells (DCs), the most potent antigen-presenting cells, are necessary for effective activation of naïve T cells. DCs’ immunological properties are modulated in response to various stimuli. Active DNA demethylation is crucial for DC differentiation and function. Vitamin C, a known cofactor of ten-eleven translocation (TET) enzymes, drives active demethylation. Vitamin C has recently emerged as a promising adjuvant for several types of cancer; however, its effects on human immune cells are poorly understood. In this study, we investigate the epigenomic and transcriptomic reprogramming orchestrated by vitamin C in monocyte-derived DC differentiation and maturation. Vitamin C triggers extensive demethylation at NF-κB/p65 binding sites, together with concordant upregulation of antigen-presentation and immune response-related genes during DC maturation. p65 interacts with TET2 and mediates the aforementioned vitamin C-mediated changes, as demonstrated by pharmacological inhibition. Moreover, vitamin C increases TNFβ production in DCs through NF-κB, in concordance with the upregulation of its coding gene and the demethylation of adjacent CpGs. Finally, vitamin C enhances DC’s ability to stimulate the proliferation of autologous antigen-specific T cells. We propose that vitamin C could potentially improve monocyte-derived DC-based cell therapies.

INTRODUCTION

Dendritic cells (DCs) play a central role in the immune system, bridging innate and adaptive immune responses. As innate immune cells, they are able to recognize a plethora of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) through pattern recognition receptors (PRRs) (1). Moreover, they are very efficient at antigen processing and presentation to T cells and are, therefore, responsible for initiating antigen-specific immune responses.

DCs are highly heterogeneous, and comprise plasmacytoid DCs (pDCs) and conventional DCs (cDCs). Furthermore, monocyte-derived DCs (moDCs) can be differentiated in vitro from monocytes (MOs), with GM-CSF and IL-4 (2). moDCs have been classically used as a convenient model that mimics blood DCs, especially cDC2 (3). However, increasing evidence indicates that MOs can extravasate to peripheral tissues and give rise to bona fide moDCs in vivo (4).

Changes in DNA methylation, mainly active DNA demethylation, are involved in several differentiation processes from MOs, leading to macrophages (5), osteoclasts (6) and DCs (7) and are crucial for immune cell differentiation, identity, and function (8). In general, DNA demethylation is more extensive during MO differentiation than during subsequent maturation/activation (7). Additionally, the maturation of moDCs with live bacteria produces DNA demethylation that follows gene activation, limiting the potential direct regulatory effects of DNA methylation in such a context (9). TET2, a member of the Ten-Eleven Translocation (TET) methylcytosine dioxygenases,
has been pointed out as the main enzyme involved in multi-step active demethylation processes in terminal MO-related differentiation processes (6,10). However, recent data indicate that TET3 might complement TET2-mediated activity during MO differentiation (11). Recently, TET2 has also been implicated in glucocorticoid- and vitamin D-mediated modulation of the immunogenic properties of DCs (12,13).

Vitamin C (L-ascorbic acid) is an essential nutrient with pleiotropic functions. Its deficiency is associated with a disease, namely scurvy, characterized by a plethora of symptoms, including the malfunction of the immune system. For instance, the normal intracellular level of vitamin C in MO cytoplasm is ~3 mM, 60 times higher than the plasma level, reflecting a specific function of the molecule in immune cell biology (14). Vitamin C can act as a cofactor of Fe-containing hydroxylases such as TET enzymes and Jumonji C domain-containing histone demethylases (JHMDs), enhancing their catalytic activity (15). Some studies in mice suggest that vitamin C can stimulate DC capacity to produce proinflammatory cytokines and promote differentiation of T cells (16). Moreover, vitamin C intravenous treatment in mice has been shown to abrogate cancer progression through direct TET2 function restoration in cancer cells (17) and immune system modulation (18).

The in vivo modulation of DC migration and function, and the administration of DC-based vaccines, are potential strategies to treat different types of cancer (19). In particular, autologous moDCs obtained ex vivo from patient-derived blood MOs have been used in several clinical trials with mixed results (20–22). In this regard, the improvement of moDC generation in vitro, and the use of molecules to modulate MO differentiation in vivo may boost the clinical outcome of cancer patients.

In this work, we have investigated the effects of vitamin C treatment during MO-to-DC in vitro differentiation and maturation, identifying extensive DNA demethylation associated with the upregulation of migration, chemotaxis, antigen presentation, and immune response-related genes. Moreover, vitamin C-mediated DNA demethylation, gene upregulation, and increased TNFβ production during DC maturation were associated with p65, a component of the NF-κB complex that interacts with TET2 in this context. We have shown that the modulation of DNA methylation changes during DC differentiation and maturation yields functional and phenotypic changes in these cells, improving their immunogenicity.

**MATERIALS AND METHODS**

**CD14* monocyte purification and culture**

Buffy coats were obtained from anonymous donors via the Catalan Blood and Tissue Bank (CBTB). The CBTB follows the principles of the World Medical Association (WMA) Declaration of Helsinki. Before providing blood samples, all donors received detailed oral and written information and signed a consent form at the CBTB.

PBMCs were isolated by density-gradient centrifugation using lymphocyte-isolation solution (Rafer). Pure MOs were then isolated from PBMCs by positive selection with magnetic CD14 MicroBeads (Miltenyi Biotec). Purity was verified by flow cytometry, which yielded >95% of CD14* cells.

MOs were resuspended in Roswell Park Memorial Institute (RPMI) Medium 1640+ GlutaMAX™ (Gibco, ThermoFisher) and immediately added to cell culture plates. After 20 min, monocytes were attached to the cell culture plates, and the medium was changed with RPMI containing 10% fetal bovine serum (Gibco, ThermoFisher), 100 units/ml penicillin/streptomycin (Gibco, ThermoFisher), 10 ng/ml human GM-CSF (PeproTech) and 10 ng/ml human IL-4 (PeproTech). In the case of the cells treated with vitamin C, 500 μM (+)-sodium L-ascorbate (Sigma-Aldrich) was also added to the medium. For dendritic cell maturation, LPS (10 ng/ml) was added to cell culture on day 5.

Cells were collected on day 2 (designated as Ø/ØvitC, given their incomplete differentiation status) and on day 7, including immature dendritic cells (iDC/iDCvitC) and mature dendritic cells, with LPS stimulus (mDC/mDCvitC).

**Genomic DNA and total RNA extraction**

Genomic DNA and total RNA were extracted using the Maxwell RSC Cultured Cells DNA kit (Promega) and the Maxwell RSC simplyRNA Cells kit (Promega), respectively, following the manufacturer’s instructions.

**NF-κB chemical inhibition**

Bay 11–7082 (Sigma-Aldrich) was used for NF-κB inhibition. The compound was diluted in DMSO to 50 mM. Bay 11–7082 at 10 μM or an equivalent amount of diluent were used as final concentrations.

MOs were differentiated to iDCs/iDCvitC as previously described. On day 5, LPS, Bay 11–7082 or equivalent amounts of diluents were added to the cell culture for 2 days, yielding iDC/iDCvitC, iDC + Bay/iDCvitC + Bay, mDC/mDCvitC, and mDC + Bay/mDCvitC + Bay.

**DNA methylation profiling**

500 ng of genomic DNA was converted using the EZ DNA Methylation Gold kit (Zymo Research), using 4 biological replicates for each group. Infinium MethylationEPIC BeadChip (Illumina) arrays were used to analyze DNA methylation, following the manufacturer’s instructions. This platform allows around 850 000 methylation sites per sample to be interrogated at single-nucleotide resolution, covering 99% of the reference sequence (RefSeq) genes. Raw files (IDAT files) were provided for the Josep Carreras Research Institute Genomics Platform (Barcelona).

Quality control and analysis of EPIC arrays were performed using ShinyEPICo (23) a graphical pipeline that uses minfi (24) for normalization, and limma (25) for differentially methylated positions analysis. CpH and SNP loci were removed and the Noob + Quantile normalization method was used (26,27). After quality control, 831 421 CpGs were preserved for the analysis. Donor ID was used as a covariate, and Trend and Robust options were enabled for the eBayes moderated t-test analysis. CpGs were considered differentially methylated when the absolute differential of
methylated was $>30\% (\Delta \beta > 0.3)$ and the FDR was $<0.05$. Infinium MethylationEPIC BeadChip arrays were designed using the hg19 human genome. For some downstream analysis, the genomic coordinates were converted to hg38 using the LiftOver tool (28).

For the genome-wide DNA methylation study after NF-κB chemical inhibition, the same experimental approach and normalization pipeline was followed. After quality control, 812 429 CpGs were preserved for the analysis.

RNA-seq

RNA-seq libraries of MOs, Ø/Ø vítC, iDC/iDC vítC and mDC/mDC vítC were generated and sequenced by Novogene (Cambridge), in 150-bp paired-end, with the Illumina NovaSeq 6000 platform, using three biological replicates for each group. More than 40 million reads were obtained for each sample. Fastq files were aligned to the hg38 transcriptome using HISAT2 (29) with standard options. Reads mapped in proper pair and primary alignments were selected with SAMtools (30). Reads were assigned to genes with featureCounts (31).

Differentially expressed genes were detected with DESeq2 (32). The donor was used as a covariate in the model. The Ashr shrinkage algorithm was applied and only protein-coding genes with an absolute logFC $>0.5$ and an FDR less than 0.05 were selected as differentially expressed. For representation purposes, Variance Stabilizing Transformation (VST) values and normalized counts provided by DESeq2 were used.

Quantification of cytokine production

Cell culture supernatants were collected after 7 days and diluted appropriately. Enzyme-linked immunosorbent assays (ELISA) were performed to detect TNFβ, following the manufacturer’s instructions (TNF beta Human ELISA Kit, ThermoFisher).

T cell clonal expansion and proliferation assay

PBMCs from healthy donors were purified from blood by density gradient centrifugation. The PBMCs (1 ml; $3 \times 10^6$ cells per well) were cultured in the presence of SARS-CoV-2-S (9 pmol) (PepTivator) in 24-well plates and maintained in IMDM medium (Gibco) supplemented with penicillin (100 units/ml), streptomycin (100 mg/ml) and human serum (10%) (Millipore) in the absence of IL-2 for 3 days. After 3 days, 1 ml of medium with 80 U/ml of recombinant human IL-2 (PeproTech) was added to the wells, with a final concentration of $1.5 \times 10^6$ cell/ml and 40 U/ml of IL-2. After 7–10 days of culture, T cells were expanded in the presence of 30-Gy irradiated autologous PBMCs (3 $\times 10^6$ cells/well) previously pulsed with 9 pmol of SARS-CoV-2-S (PepTivator). Antigen-specific T cells (mix of CD4+ and CD8+ T cells) were selected by performing the same protocols two times to have a positive selection.

After 7 days of differentiation and activation, DCs were washed to remove vitamin C and were co-cultured with antigen-specific autologous CFSE-stained T cells at a DC: T cell ratio of 1:2 in 200 μl of RPMI 1640 medium containing 10% FBS, penicillin (100 units/ml), streptomycin (100 mg/ml) in round bottom 96-well plates (ThermoFisher). Co-culture was performed in the presence of SARS-CoV-2-S antigen or SARS-CoV-2-N control antigen (PepTivator).

T cell proliferation was analyzed by FACS and determined by considering the proliferating of those where CFSE staining had decreased compared to not co-cultured T cells. T cells stimulated with anti-CD3/CD28 microbeads 5 μg/ml (eBioscience) were used as a positive control.

Flow cytometry

To study cell-surface markers, cells were collected using Versene, a non-enzymatic dissociation buffer (ThermoFisher). Cells were resuspended in the staining buffer (PBS with 4% fetal bovine serum and 2 mM ethylenediaminetetraacetic acid (EDTA)). Cells were then incubated on ice with an Fc block reagent (Miltenyi Biotec) for 10 minutes, and stained with the proteins of interest, using the following antibodies: CD8 (FITC) (#21270083, Becton Dickinson), and CD4 (APC) (#555349, BD Biosciences). After staining, cells were analyzed using a BD FACSCanto™ II Cell Analyzer (BD Biosciences). Data were analyzed with the FlowJo v10 software.

Bisulfite pyrosequencing

500 ng of genomic DNA was converted using the EZ DNA Methylation Gold kit (Zymo Research). PCR was performed using the bisulfite-converted DNA as input and primers designed for each amplicon (Supplementary Table 1). These primers were designed using the PyroMark Assay Design 2.0 software (Qiagen). PCR amplicons were pyrosequenced using the PyroMark Q48 system and analyzed with PyroMark Q48 Autoprep software.

Real-time quantitative reverse-transcribed polymerase chain reaction (qRT-PCR)

300 ng of total RNA were reverse-transcribed to cDNA with Transcriptor First Strand cDNA Synthesis Kit (Roche) following the manufacturer’s instructions. qRT-PCR was performed in technical triplicates for each biological replicate, using LightCycler® 480 SYBR Green Mix (Roche), and 7.5 ng of cDNA per reaction. The average value from each technical replicate was obtained. Then, the standard double-delta Ct method was used to determine the relative quantities of target genes, and values were normalized against the control genes RPL38 and HPRT1. Custom primers were designed to analyze genes of interest (Supplementary Table 1).

Co-immunoprecipitation (Co-IP)

Co-IP assays were performed using mDCs and mDC vítC after 5 days of differentiation from MOs and 24 h of stimulation with LPS. Cell extracts were prepared in lysis buffer [50 mM Tris–HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1% Triton-X-100, protease inhibitor cocktail (cOmplete™, Merck)] with corresponding units of Benzonase (Sigma) and incubated at 4°C for 4 h. 100 μl of supernatant was saved as input and diluted with 2× Laemmli sample buffer
(5× SDS, 20% glycerol, 1 M Tris–HCl (pH 8.1)). Supernatants were first precleared with PureProteome™ Protein A/G agarose suspension (Merck Millipore) for 1 h. The lysis was then incubated overnight at 4°C with respective crosslinked primary antibodies. The cross-linking was performed in 20 mM dimethyl pimelimidate (DMP) (Pierce, Thermo Fisher Scientific, MA, USA) dissolved in 0.2 M sodium borate (pH 9.0). Subsequently, the beads were quenched with 0.2 M of ethanolamine (pH 8.0) and resuspended at 4°C in PBS until use. Beads were then washed three times with lysis buffer at 4°C. Sample elution was done by acidification using a buffer containing 0.2 M glycine (pH 2.3) and diluted with 2× Laemmli. Samples and inputs were denatured at 95°C in the presence of 1% β-mercaptoethanol. Anti-p65 C15310256 (Diagenode) and control IgG C15410206 (Diagenode) were used for co-IP.

Chromatin immunoprecipitation

On day 6, after 5 days of differentiation and 24 h of maturation with LPS or an equivalent amount of dimunt, iDC, iDCwithmDC and mDCwith were fixed with Pierce™ fresh methanol-free formaldehyde (ThermoFisher) for 15 min and prepared for sonication with the truChIP Chromatin Shearing Kit (Covaris), following the manufacturer’s instructions. We performed chromatin immunoprecipitation assays at 24 h of LPS-mediated maturation to capture the binding occurring before the final time point (48 h). Chromatin was sonicated 18 min with the Covaris M220 in 1 ml milliTubes (Covaris). The size distribution of the sonicated chromatin was checked by electrophoresis to ensure an appropriate sonication, with a size around 200 bp.

Magna Beads Protein A + G (Millipore) were blocked with PBS + BSA (5 mg/ml) for 1 h. Chromatin was pre-cleared with 25 μl of beads for 1.5 h and 10 μg of chromatin were incubated overnight with each antibody: 10 μl Anti-p65 antibody ab16502 (Abcam), in a buffer with 1% Triton X-100, 150 mM NaCl and 0.15% SDS. Three washes were performed with the Low Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, pH 8.0, 20 mM Tris–HCl pH 8.0, 150 mM NaCl), the High Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, pH 8.0, 20 mM Tris–HCl pH 8.0, 500 mM NaCl) and the LiCl Wash Buffer (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA pH 8.0, 10 mM Tris–HCL), followed by a last wash with TE buffer (pH 8.0, 10 mM Tris–HCl, 1 mM EDTA). Chromatin was eluted for 45 min 65°C with 100 μl of elution buffer (10 mM Tris–Cl, 1 mM EDTA, 1% SDS) and decrosslinked adding 5 μl 5 M NaCl and 5 μl 1 M NaHCO3 (2 h 65°C). Next, 1 μl of 10 mg/ml protease K (Invitrogen) was added, and samples were incubated at 37°C for 1 h. For DNA purification, iPure kit v2 (Diagenode) was used, following the manufacturer’s instructions. 1% of the chromatin input from each sample was purified by the same method.

For ChIP-qPCR, samples were diluted 1/10, and 4 μl and specific primers (Supplementary Table 1) were used for each reaction. qRT-PCR was performed in technical triplicates for each biological replicate, using LightCycler® 480 SYBR Green Mix (Roche). The relative amount of immunoprecipitated DNA compared to input was calculated with the following formula: 

\[ \text{IP} = \left( \frac{C_{\text{input}} - 6.64}{C_{\text{sample}}} \right) \times 100\% \]

Western blotting

Cytoplasmic and nuclear protein fractions were obtained using hypotonic lysis buffer (Buffer A; 10 mM Tris pH 7.9, 1.5 mM MgCl2, 10 mM KCl supplemented with protease inhibitor cocktail (Complete, Roche) and phosphatase inhibitor cocktail (PhosSTOP, Roche) to lyse the plasma membrane. Cells were visualized in the microscope to ensure correct cell lysis. The nuclear pellets were resuspended in Laemmli 1× loading buffer. For whole-cell protein extract, cell pellets were directly resuspended in Laemmli 1× loading buffer.

Proteins were separated by SDS-PAGE electrophoresis. Immunoblotting was performed on polyvinylidene difluoride (PVDF) membranes following standard procedures. Membranes were blocked with 5% Difco™ Skim Milk (BD Biosciences) and blotted with primary antibodies. After overnight incubation, membranes were washed three times for 10 min with TBS-T (50 mM Tris, 150 mM NaCl, 0.1% Tween-20) and incubated for 1 h with HRP-conjugated mouse or rabbit secondary antibody solutions (Thermo Fisher) diluted in 5% milk (diluted 1/10 000). Finally, proteins were detected by chemiluminescence using WesternBright™ ECL (Advansta). The following antibodies were used: Anti-p65 C15310256 (Diagenode), Anti-phosphorylated p65 (Ser536) 93H1 (Cell Signaling), Anti-GAPDH 2275-PC-100 (Trevigen), Anti-TET2 C15200179 (Diagenode), Anti-histone H1 ab4269 (Abcam), Anti-beta Actin ab8227 (Abcam). Protein quantification was performed with ImageJ/Fiji (33).

Data analysis and representation

Statistical analyses were performed in R 4.0.3. Gene expression and DNA methylation heatmaps were created with the heatmap.2 function of the gplots package. The findMotifsGenome.pl function of HOMER (Hypergeometric Optimization of Motif EnRichment) was used to analyze known motif enrichment, using the parameters ‘-size 200 -cpg. All EPIC array CpG coordinates were also used as background for the methylation data. GREAT software was used to calculate CpG-associated genes and gene ontology (GO) enrichment (34). GO enrichment of gene expression data was performed using the clusterProfiler package (35). ChiP-seq peaks files of histone marks from MO, iDCs, and mDCs were downloaded from the BLUEprint webpage (http://dcc.blueprint-epigenome.eu). Consensus peaks of the different replicates were obtained with the MSPC algorithm (36), using the options ‘-r Biological -w 1E-4 -s 1E-8 -c 3′.

The chromatin state learning model for CD14+ monocytes was downloaded from the Roadmap Epigenomics Project webpage, and chromatin state enrichments were calculated using Fisher’s exact test.

Public DNAase-seq and ATAC-seq bigwigs were aggregated using wiggletools (37) to obtain the mean value of several replicates. Heatmaps were generated with deepools (38).
RESULTS

Vitamin C drastically enhances DNA demethylation during monocyte to dendritic cell differentiation and maturation

MOs isolated from peripheral blood of healthy donors were differentiated in vitro to DCs for 7 days using GM-CSF and IL-4, in the presence or absence of vitamin C (vitC). Samples were collected on day 2, in the middle of the differentiation (designated as Ø/vitC given their incomplete differentiation), and on day 7, including immature DCs (iDCs) (iDC/iDCvitC), without further treatment, and mature DCs, exposed the last 48 h to lipopolysaccharide (LPS) (mDC/mDCvitC) (Figure 1A).

DNA methylation was profiled using Illumina Infinium MethyEPIIC arrays, which covered 831 421 CpG sites in the human genome, after the quality control. First, overall changes in DNA methylation were calculated between groups pairwise (Supplementary Figure 1A). DNA demethylation was the most prominent change, as previously described (7). We then compared the demethylated positions in MO-to-iDC differentiation, in comparison with MO-to-iDCvitC differentiation, as well as iDC-to-mDC maturation in comparison with iDCvitC-to-mDCvitC maturation. As it can be observed, the positions demethylated in the differentiation and maturation processes in the presence of vitamin C include the majority of CpGs demethylated in the regular differentiation and maturation of DCs, as well as a vast number of additional CpGs (Figure 1B).

Principal component analysis (PCA) revealed that on day 2, most DNA methylation variance of the MO-to-iDC differentiation had already developed (Figure 1C), whereas no differences with the vitamin C stimulus were found. In contrast, on day 7, vast differences were observed for both iDCvitC and mDCvitC, in comparison with their corresponding controls without vitamin C suggesting that the vitamin C-mediated boost in demethylation occurs later in time. The variable that explains most of the variance in DNA methylation resides in the presence/absence of vitamin C during differentiation.

All differentially methylated positions (DMPs) associated with vitamin C (iDC versus iDCvitC and mDC versus mDCvitC) were represented together, revealing two clusters of DMPs (M1 and M2) (Figure 1D and Supplementary Table 2). M1 corresponds with CpGs demethylated during differentiation in the presence of vitamin C whereas M2 are CpGs demethylated during LPS-mediated maturation in the presence of vitamin C. Both clusters were enriched in monocyte enhancers and regions flanking active transcription start sites (Figure 1E). That corresponds with predominant localization in intergenic regions, far from CpG islands (Supplementary Figure 1B and Supplementary Figure 1C). Of note, M1 and M2 DMPs are located in regions with subtle increases in H3K27ac and H3K4me1 histone marks from MOs to iDCs and mDCs, respectively. This suggests that these regions are primed for activation, even in the absence of vitamin C (Supplementary Figure 1D).

Gene Ontology enrichment analysis of M1 DMP-associated genes revealed categories related to positive regulation of myeloid differentiation, regulation of JAK activation, regulation of defense response to virus, and vitamin transport, among others. In contrast, M2 DMPs were enriched in terms related to LPS response and immune activation such as cellular response to molecules of bacterial origin, leukocyte activation, response to bacteria, regulation of IFNγ production, and positive regulation of NF-κB activity (Figure 1F). These functions are consistent with the respective association of M1 and M2 clusters with the DC differentiation and maturation steps.

Active demethylation in myeloid cells is often mediated by transcription factors that recruit specific epigenetic enzymes. In this regard, M1 DMPs were enriched in the consensus binding motifs of transcription factors previously related to DC differentiation, such as EGR2(11), STAT6(7), and PU.1(11), whereas M2 DMPs were enriched in the consensus binding motifs of NF-κB, AP-1 and IRF (Figure 1G). Employing the average signal of public MO DNAseq (Blueprint database) (39) and iDC ATAC-seq triplicates (40), we found that M1 and M2 DMPs present low accessibility in MOs (Supplementary Figure 1E). We also observed that M1 DMPs have greater accessibility than M2 DMPs in iDCs (Supplementary Figure 1F).

Vitamin C drives gene expression remodeling in dendritic cells

Given the extensive differences in DNA methylation mediated by vitamin C, we then performed RNA-seq of MOs, Ø, ØvitC, iDC, iDCvitC, mDC and mDCvitC and checked for differences in their transcriptomes. In contrast with DNA methylation, transcriptome variance of principal component (PC1) and PC2 are mainly explained by the maturation of DCs and the differentiation of MO to DC, respectively. However, differences between iDC and iDCvitC and mDC and mDCvitC can also be observed in the PCA (Figure 2A).

We first checked the expression patterns of the transcription factors related to the motifs enriched in the M1 and M2 DMPs (Figure 1G). We could observe that most of these transcription factors are more expressed than the median gene expression in the dataset, with the exception of WT (WT1), SPIB and Nur77 (NR4A1) which are lowly expressed in dendritic cells (Supplementary Figure 2A).

Since samples were collected on day 2 (Ø/vitC), and on day 7, without (iDC/iDCvitC) or with (mDC/mDCvitC) LPS-mediated activation, three potential comparisons of vitamin C-treated cells can be performed, in relation to their respective controls. On day 2, very few differences were found between Ø and ØvitC (63 downregulated and 75 upregulated genes). On day 7, we found 163 downregulated and 159 upregulated genes between iDC and iDCvitC, whereas most differences were found between mDC and mDCvitC (185 downregulated and 772 upregulated genes) (Figure 2B, Supplementary Table 3). Furthermore, most differentially expressed genes (DEGs) were not shared between comparisons (Figure 2C).

We then joined the differentially expressed genes of the three comparisons. We used hierarchical clustering and the elbow method to decide an appropriate number of clusters.
Figure 1. Vitamin C-mediated dendritic cell DNA methylation remodeling. (A) Scheme depicting the experimental setup. Monocytes (MO) were differentiated to dendritic cells (iDCs) using GM-CSF and IL-4, in the presence or absence of vitamin C (vitC). Samples were collected on day 2, in the middle of the differentiation, and on day 7, including immature DCs (iDCs) and mature DCs (mDCs), exposed the last 2 days to lipopolysaccharide (LPS). (B) Area-proportional Venn diagrams comparing the demethylated CpG sets of MO-to-iDC versus MO-to-iDCvitC, and iDC-to-mDC versus iDCvitC-to-mDCvitC transitions. (C) Principal Component Analysis (PCA) of differentially methylated positions (DMPs) comparing all groups pairwise. Principal component 1 and principal component 2 are represented on the x- and y-axis, respectively. Solid and dashed lines represent the trajectories across MO-iDC-mDC and MO-iDCvitC-mDCvitC differentiation/maturation respectively, to make the plot easier to follow. (D) DNA methylation heatmap of DMPs comparing iDC to iDCvitC, and mDC to mDCvitC ($\Delta \beta \geq 0.3$, FDR < 0.05). Scaled $\beta$-values are shown (lower DNA methylation levels in blue and higher methylation levels in red). On the right side, violin plots of clusters M1 and M2 depict scaled $\beta$-values. (E) Enrichment of M1 and M2 DMPs in ChromHMM 15-states categories of MOs (Roadmap Epigenomics Project). Fisher’s exact tests of M1 and M2 DMPs were calculated using all the CpGs annotated in the EPIC array as background. Significantly enriched categories (FDR < 0.05 and odds ratio > 2) are depicted with a black stroke, including TxFlnk (Flanking Active TSS), TxWk (Weak Transcription), EnhG (Genic Enhancers), and Enh (Enhancers). (F) GO (Gene Ontology) over-represented categories in M1 and M2 DMPs. Fold Change in comparison with background (EPIC array CpGs) and $-\log_{10}$(FDR) is represented. (G) Bubble scatterplot of transcription factor binding motif enrichment for M1 and M2 DMPs. The x-axis shows the percentage of windows containing the motif and the y-axis shows the fold enrichment of the motif over the EPIC background. Bubbles are colored according to the transcription factor family. FDR is indicated by bubble size.
Figure 2. Shifting in gene expression of dendritic cells triggered by vitamin C. (A) Principal Component Analysis (PCA) of gene expression. Principal component 1 and principal component 2 are represented on the x- and y-axis, respectively. Solid and dashed lines represent the trajectories across MO-iDC-mDC and MO-iDCvitC-mDCvitC differentiation/maturation respectively, to make the plot easier to follow. (B) Volcano plots of gene expression in the iDC vs. iDCvitC and the mDC versus mDCvitC comparisons. The binary logarithm of the fold change is represented on the y-axis, whereas the negative decimal logarithm of the FDR is represented on the x-axis. Downregulated genes are shown in blue (FDR < 0.05, Fold Change < -2) and upregulated genes are shown in orange (FDR < 0.05, Fold Change > 2). (C) Area-proportional Venn diagrams comparing the upregulated and downregulated genes sets of the Ø versus ØvitC, iDC versus iDCvitC and mDC vs. mDCvitC comparisons. (D) Gene expression heatmap of differentially expressed genes comparing Ø to ØvitC, iDC to iDCvitC, and mDC to mDCvitC (absolute log FC > 1, FDR < 0.05). Scaled expression VST values are shown (lower expression levels in green and higher expression values in orange). The division of the dendrogram created with the ward.D2 agglomeration method yielded six different expression clusters (E1–E6). (E) Temporal progression of gene expression of the expression clusters (E1–E6) during the differentiation process with (orange) or without (blue) vitamin C. The y-axis shows VST values, where a higher value means a higher gene expression, and the line ribbons represent the 95% confidence interval. (F) Gene Ontology (GO) over-representation of GO Biological Process categories in the E1–E6 clusters. Fold Change of genes over the background and –log10(FDR) of the Fisher's exact tests are shown. Significant categories (FDR < 0.01) are depicted with a black stroke.

(Supplementary Figure 2B). We then divided the genes into six clusters (expression clusters E1–E6) with different behaviors (Figure 2D and Supplementary Table 4). E1, E2 and E3 clusters show a diminished downregulation trend in the iDCvitC to mDCvitC transition, in comparison with the iDC to mDC transition, whereas E5 genes are more upregulated in the iDCvitC to mDCvitC transition in comparison with the iDC to mDC transition (Figure 2E).

Gene Ontology Enriched terms were calculated for each expression cluster, obtaining distinctive categories (Figure 2F). For instance, E1 was enriched in dendritic cell migration and chemotaxis, E2 in macrophage activation and cytokine secretion, E3 in antigen processing and presentation and response to calcium ion, and E5 in type I interferon signaling pathway and defense response to virus.

Vitamin C-mediated demethylation is linked to increased gene expression during dendritic cell maturation

To identify potential functional effects of the vitamin C-mediated demethylation, we linked each DMP with its closest gene. When the global profile of M1 and M2 associated genes was intersected with DEGs from Figure 2D, we found that M1 associated genes are less downregulated in mDCs with vitamin C treatment, whereas M2 associated genes are upregulated in mDCs with vitamin C treatment.
(Figure 3A). Concordantly, E1 and E2 clusters are enriched in M1-associated genes, and the E5 cluster is enriched in M2-associated genes (Figure 3B).

Individual DMPs and their associated DEGs illustrate different relationships between DNA methylation/gene expression. M1-associated genes, C1QB and CD1C, which are related to the complement system and antigen presentation respectively, show demethylation with vitamin C treatment in iDCs, conjoined with a lower reduction in expression after activation (Figure 3C). Furthermore, M2-associated genes such as LTA, IKKBE and IRF8 related to TNFβ production, NF-κB pathway regulation, and interferon regulation respectively, depict a decreased methylation in mDC with vitamin C, concomitant with increased gene expression (Figure 3D).

Finally, a database of transcription factor regulation (41) was used to infer potential transcription factors involved in regulating expression clusters (Figure 3E and Supplementary Figure 3A). Interestingly, PU.1 and RELA (p65) were associated with M1/E2 and M2/E5 clusters, respectively.

**NF-κB/p65 orchestrates vitamin C-mediated DNA demethylation, gene upregulation and increased proinflammatory cytokine production**

Since p65 was associated with both DNA demethylation (Figure 1G) and gene upregulation (Figure 3E) during mDCvitC maturation, we studied the protein expression and phosphorylation by Western Blot. First, we found that p65 presents similar protein levels in iDCs, mDCs, iDCvitC and mDCvitC. However, phosphorylated p65 (Ser536) (p-p65) is increased in both mDCs and mDCvitC (Figure 4A and Supplementary Figure 4A). Moreover, we also detected p-p65 in the nuclear fraction (NF) of mDCs and mDCvitC, enabling it to act as a transcription factor (Figure 4B and Supplementary Figure 4A).

To further explore the role of NF-κB/p65 in the mDCvitC transcriptomic and epigenomic reprogramming, we utilized a chemical inhibitor of IκB degradation (BAY 11-7082, Bay) which reduces the nuclear translocation of p65 (42,43) (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Figure 4F and Supplementary Figure 4D). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) which reduces the nuclear translocation of p65 (Supplementary Figure 4B).

To further explore the role of NF-κB/p65 in the mDCvitC transcriptomic and epigenomic reprogramming, we utilized a chemical inhibitor of IκB degradation (BAY 11-7082, Bay) which reduces the nuclear translocation of p65 (42,43) (Supplementary Figure 4B). MOs were differentiated in DCs as previously described, adding Bay (BAY 107082, Bay) or Dimethyl Sulfoxide (DMSO) on day 5 (Figure 4C).

We then tested the effect of NF-κB inhibition on M1 and M2 DMPs. We observed that the NF-κB inhibitor dampens the demethylation of M2 DMPs, concordantly with their enrichment in NF-κB motifs. However, this effect is smaller in M1 DMPs (Figure 4D). Specifically, NF-κB inhibition pervasively prevents the demethylation of most M2 DMPs (P < 1^{-1}) (Figure 4E). As a validation, we performed pyrosequencing of selected DMPs from the M2 cluster, observing the blockage of demethylation. Conversely, a DMP from the M1 cluster was not affected (Supplementary Figure 4C).

Secondly, we also tested the expression of M2-associated genes revealing that, inversely to DNA demethylation, gene expression decreases in mDCvitC when NF-κB is inhibited (Figure 4F and Supplementary Figure 4D). However, the same trend was not found in M1-associated genes (Figure 4F and Supplementary Figure 4E).

We then checked the potential interaction between p65 and TET2, a key mediator of active demethylation in myeloid cells whose activity is enhanced by vitamin C. The co-immunoprecipitation of p65 revealed its interaction with TET2 in both mDCs and mDCvitC (Figure 4G).

Additionally, we performed a ChIP-qPCR analysis of p65 on day 6, comparing the binding in a negative control amplicon around the INS gene with an amplicon around the eg08639424, located close to LTA and TNF genes. p65 was significantly enriched in mDCs/iDCvitC, but not in iDCs/iDCvitC (Figure 4H).

Since the LTA gene, which encodes TNFβ, was found up-regulated and the adjacent CpGs become demethylated in mDCvitC, we measured the TNFβ protein levels secreted by these cells in comparison with mDCs. mDCs produced little amounts of TNFβ whereas mDCvitC supernatant contained considerably higher concentrations (Figure 4I). Moreover, Bay treatment damped TNFβ production of mDCvitC, consistent with the reversion in the eg08639424 demethylation and LTA upregulation (Supplementary Figure 4F).

**Vitamin C produces dendritic cells with higher T cell stimulation capabilities**

We then characterized the mDCvitC phenotype in comparison with mDCs. In particular, we studied the T cell stimulation capabilities and antigen presentation of mDCvitC in contrast to mDCs. First, we performed a clonal expansion of T cells from healthy donors with a SARS-CoV-2 mix of antigens. After the process, we verified that 95% of the resulting cells were T lymphocytes by staining them with anti-CD4 and anti-CD8 antibodies (Supplementary Figure 5A and Supplementary Figure 5B). We then differentiated autologous MOs in vitro to iDCvitC/iDCs. After 48 h of maturation with LPS and 1 h of antigen loading with the same SARS-CoV-2 antigen mix, mDCvitC/mDCs were cocultured with Carboxyfluorescein succinimidyl ester (CFSE)-stained clonal T cells for 5 days (Figure 5A).

In Figure 5B, a selected example of this T cell proliferation assay is shown. The histogram of the CFSE signal of T cells alone (C’) or cocultured with mDC/mDCvitC loaded with a control antigen or with the specific set of antigens (An) is depicted.

Overall, we observed a significant increase in T cell proliferation when they are cocultured with mDCvitC loaded with a specific set of antigens, in comparison with mDCs loaded with the same antigens. This can be observed by the increase in the proliferation percentages and the decrease in the median intensity of fluorescence (MFI) of CFSE (Figure 5C and D). However, when T cells were cocultured with mDCs/iDCvitC loaded with a control antigen, no differences in proliferation or MFI were found, indicating that the mDCvitC increased T cell activation capabilities rely on specific antigen presentation and not only indirect stimulation (Figure 5C, D).

**DISCUSSION**

In this work, we demonstrate a substantial effect of vitamin C supplementation during the MO-to-DC in vitro differentiation and maturation. First, we show vast demethylation in DCs treated with vitamin C, consistent with its role as a TET enzyme cofactor, being the number of additional
demethylated CpGs higher than the MO-to-DC demethylation without vitamin C. This epigenomic remodeling correlates with increased expression of genes related to antigen presentation, cytokine secretion, and immune response. Moreover, our analysis indicates that NF-kB is directly involved in the epigenomic and transcriptomic reprogramming observed during the maturation of DCs in the presence of vitamin C, together with the increase in TNFα production. Finally, vitamin C enhances the capacity of DCs to induce the proliferation of autologous T cells through specific antigen presentation.

Vitamin C is a well-established cofactor of TET proteins, with the ability to enhance TET-mediated oxidation of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and further oxidized methylcytosine derivatives (44,45). Given the absence of proliferation in the MO-to-DC differentiation process (13), the observed demethylation should occur through an active mechanism, consistent with previous studies, and be catalyzed by TET enzymes, the activity of which is enhanced by vitamin C. We and others have shown that TET2, the most expressed TET enzyme in MOs, is the major driver of active demethylation in this biological context (7,10,46). In this study, we show the physical interaction between TET2 and p65, one of the NF-kB subunits, that is associated with the CpGs that become demethylated during DC activation in the presence of vitamin C. However, we cannot discard the participation of other TET enzymes in the demethylation process, whose enzymatic activity could also be enhanced by vitamin C. In fact, TET3 could compensate for TET2 activity during MO differentiation (11).

Of note, the observed effects of vitamin C on DNA methylation occur in the last days of the differentiation process, since no DNA methylation differences were found
Figure 4. Role of p65 in the transcriptomic and epigenomic remodeling of vitamin C-treated dendritic cells. (A) Western blot of phosphorylated p65 (p-p65) (Ser536) and total p65 in whole-cell lysates. β-actin was used as a loading control. (B) Western blot of p-p65 in the nuclear (NF) and cytoplasmic fractions (CF). GAPDH and histone H1 proteins were used as loading control for cytoplasms and nuclei, respectively. (C) Scheme depicting the inhibition of p65. Monocytes (MO) were differentiated to dendritic cells (DCs) using GM-CSF and IL-4, in the presence or absence of vitamin C (vitC). On day 5, lipopolysaccharide (LPS) and BAY 11–7082 (Bay) or equivalent amounts of diluent were added to the cell culture. On day 7, iDC/iDCvitC, iDC+Bay/iDCvitC+Bay, mDC/mDCvitC and mDC+Bay/mDCvitC+Bay were obtained. (D) Scatter plots of M1 and M2 DMPs showing DNA methylation (β-values) of Bay-treated (y-axis) versus untreated mDCs/mDCvitC (x-axis). Contour lines represent a 2D kernel density estimation. Labels with selected examples indicate the DMPs associated with these previously shown genes (Figure 3C, D). (E) Methylated CpG set enrichment analysis (mCSEA) of mDCvitC versus mDCvitC + Bay, using M2 DMPs as CpG set. The running enrichment score is represented and the normalized enrichment score (NES) and FDR are shown above. (F) The average gene expression of C1QB (M1-associated gene) and M2-associated genes (LTA, IKBKE and IRF8) obtained with RT-qPCR are represented with points, and the black lines indicate the standard error of the mean. P-values of paired t-tests are shown (n = 6) (ns: P > 0.05, * P < 0.05, ** P < 0.01). (G) Western blot of the co-immunoprecipitation of p65, showing the signal of p65 and TET2 proteins. Below, the image signal quantifications of three independent western blots are shown for each protein. P-values of paired t-tests are shown (n = 3) (mean ± standard error of the mean) (ns: P > 0.05, * P < 0.05, ** P < 0.01). (H) Chromatin Immunoprecipitation (ChiP) signal of p65 binding to a negative control locus (INS) and around an M2 DMPs (cg08639424) associated with LTA and TNF. The RT-qPCR signal relative to the ChiP input is shown (n = 3). P-values of t-tests are shown (n = 3) (mean ± standard error of the mean) (ns: P > 0.05, * P < 0.05). (I) TNFβ production of mDCs and mDCvitC, after 5 days of differentiation and 48h of maturation with LPS. The P-value of a Wilcoxon rank-sum test is shown (n = 3)
Figure 5. Functional and phenotypic alterations of vitamin C-treated dendritic cells. (A) Scheme depicting the T cell proliferation assay. PBMCs were obtained from healthy donors. T cell clones reacting to the specific antigen (SARS-CoV-2 protein S) were selected through several rounds of clonal expansion. On the other hand, mDCs and mDCvitC were obtained from the same donor and charged with the specific antigen. Finally, the Carboxyfluorescein succinimidylester (CFSE)-stained T cells were cocultured with mDCs/mDCvitC for 5 days. (B) Selected example of a histogram of CFSE signal from T cells, alone without stimulation (C−) or cocultured with mDC/mDCvitC treated with a control antigen or a specific set of antigens of SARS-CoV-2 (An). When T cells proliferate, the CFSE signal is diminished. The statistical analysis with all the replicates can be observed in panels C and D. (C) The proliferation of T cells cocultured with mDC/mDCvitC (2:1 proportion), with or without the loading with a specific set of antigens of SARS-CoV-2, or stimulated with CD3/CD28 activation beads (C+). P-values from two-tailed paired t-tests are shown (n = 6) (ns: P > 0.05, ** P < 0.01). (D) Median Fluorescence Intensity (MFI) of T cells alone (C−), cocultured with mDC/mDCvitC (2:1 proportion), with or without the loading with a specific set of antigens of SARS-CoV-2, or stimulated with CD3/CD28 activation beads (C+) P-values from two-tailed paired t-tests are shown (n = 6) (ns: P > 0.05, * P < 0.05).

with vitamin C treatment at day 2 of differentiation. In contrast, most variance in methylation occurring in the MO-to-iDC transition occurs before day 2 suggesting that, without vitamin C, the function of TET enzymes in this model is progressively diminished. Alternative reducing agents present in the culture medium such as glutathione are less efficient as TET cofactors (45,47). Thus, the progressive oxidation of these reducing agents may explain the impairment of TET function over time in the absence of vitamin C.

Vitamin C-mediated demethylation occurs during the differentiation (M1 cluster) or the maturation of DCs (M2 cluster). Interestingly, the sets of transcription factor motifs enriched in the M1 and M2 clusters are equivalent to the transcription factors involved in DC differentiation and LPS-mediated signaling, respectively. This suggests that, overall, vitamin C does not promote the recruitment of TET enzymes through new pathways but boosts the demethylation triggered by preexisting active signaling pathways. In fact, TET2 lacks the CXXC domain that enables direct CpG-binding of the other TETs (TET1 and TET3). In this respect, its targeting depends on transcription factors or their co-factors for locus-specific recruitment (11,48). In addition, the effect of vitamin C of preexisting active signaling pathways is highlighted by the fact that M1 and M2 DMPs are enriched in regions with increasing active chromatin marks (H3K27ac and H3K4me1) in the MO-to-iDC and the iDC-to-mDC transitions, respectively (Supplementary Figure 1D). We cannot rule out that vitamin C produces changes in histone modifications or DNA accessibility that may contribute to the phenotype. In this regard, vitamin C also increases the enzymatic activity of histone demethylases (15).

Since vitamin C can potentiate demethylation triggered by preexisting pathways, we hypothesize that this treatment may have diverse effects depending on the specific context and active transcription factors. In this regard, vitamin C could potentiate demethylation in other models of monocyte differentiation to DCs with clinical use, such as tolerogenic DCs (12,13).
The functional relationship between DNA demethylation and gene expression has been extensively studied in several biological contexts (7,9,12,13). Genes more expressed in mDCvitC than mDC, from E1 and E2 clusters are enriched in M1-associated genes. This establishes a clear temporal relationship, suggesting that prior demethylation could protect some genes from downregulation during DC maturation. On the other hand, genes from the E5 cluster are enriched in M2-associated genes. In this case, demethylation is occurring at the same step as upregulation. Then, we cannot discern whether demethylation or upregulation occurs first. However, since the primary mechanism of action of vitamin C through DNA and histone demethylation is well known, we hypothesize that epigenetic modifications could mediate gene upregulation in mDCvitC. This assumption starts from a different point than other works that established DNA demethylation during DC maturation as a consequence of gene upregulation because in this case, the differential stimulus is live bacteria, that can activate a plethora of signaling pathways not necessarily linked directly to DNA demethylation (9).

NF-κB mediates both demethylation and upregulation during the maturation of DCs in the presence of vitamin C (Figure 4D and E). Since that pathway is associated with toll-like receptor 4 (TLR4), which recognizes LPS, it is not surprising that it plays a role in the process. Intriguingly, this factor is present in the nucleus in mDCs and mDCvitC, interacts with TET2, and binds in both cases to CpGs that become demethylated only in mDCvitC. We postulate that NF-κB genomic binding in mDCs and mDCvitC is probably similar, but vitamin C potentiates TET2 function allowing the demethylation of genomic loci, which may condition the expression of the associated genes. Moreover, NF-κB also drives vitamin C-mediated production of TNFβ. This cytokine can signal through tumor necrosis factor receptor (TNFRI) and TNFRII to activate the NF-κB pathway in both DCs and T cells and has shown anti-carcinogenic properties in animal models (49–51).

Linus Pauling proposed vitamin C as a potential cancer treatment >40 years ago, but the negative results of further clinical trials diminished the enthusiasm (52,53). However, during the last few years, increasing interest has arisen around vitamin C as a treatment or adjuvant for several types of cancer. For instance, intravenous vitamin C treatment in mice abrogates cancer progression through direct TET2 function restoration in cancer cells (17). Moreover, clinical remission following vitamin C treatment was found in a case of acute myeloid leukemia with mutations in TET2 (54). Furthermore, in mice models of different types of cancer, a fully competent immune system was required to maximize the antiproliferative effects of vitamin C, suggesting an effect of that molecule in the modulation of the immune system (18). Vitamin C has already been reported to play a role in actively demethylating CNS2 in iTregs by activating TET2. Vitamin C treated iTregs could maintain high levels of Foxp3 (55–57). However, those iTregs failed to survive and maintain proper immune responses in complex GvHD models because CpG islands of non-targeted genes, probably pro-apoptotic genes, were also demethylated. Thus, clinical use of those iTregs is impractical. In this regard, in the context of DCs the observation that the implicated TFs are mainly related to differentiation and activation might confer a better outcome.

Therapies based on autologous DCs (DC vaccines) has been extensively investigated, with >200 completed clinical trials to date (19). Most efforts have been focused on cancer, but some clinical trials have also been initiated to treat infectious diseases such as COVID19 (NCT04685603, NCT05007496) (58). The use of moDCs differentiated ex vivo from monocytes of the same donor is a common and straightforward approach to generating DC vaccines, given the relatively high abundance of these cells in the human blood. However, the lower antigen presentation capabilities of moDCs in comparison with blood DCs is a bottleneck for the efficacy of these treatments (59).

Here, we show that mDCvitC loaded with SARS-CoV-2 antigens can stimulate the proliferation of autologous antigen-specific T cells more efficiently than mDCs. This indicates that vitamin C induces an increase of the antigen presentation capabilities of mDCs in an antigen-specific fashion, and could be a promising strategy for generating DC vaccines towards specific tumor antigens. These results can lead to the generation of new in vitro protocols for the generation of moDC vaccines with higher performance. However, multiple considerations should be taken into account to consider the viability of these treatments in the cancer context, including the survival of these cells and the maintenance of their enhanced immunogenic responses. Further works using animal models and human in vivo moDCs from patients treated with high doses of vitamin C should shed light on the specific clinical implications of these insights.

DATA AVAILABILITY
All DNA methylation and expression datasets for this publication have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO SuperSeries accession number GSE203463.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS
We thank CERCA Programme/Generalitat de Catalunya and the Josep Carreras Foundation for institutional support.

Author contributions: O.M.-P. and E.B. conceived and designed the study; O.M.-P., G.G.-T., J.C.-S., L.C., E.M.-P., and O.M.-P. performed experiments; O.M.-P. performed the bioinformatic analyses; O.M.-P. and E.B. wrote the manuscript; all authors participated in discussions and interpreting the results.

FUNDING
E.B. was funded by the Spanish Ministry of Science and Innovation [PID2020-117212RB-I00, AEI/10.13039/501100011033] and Instituto de Salud Carlos III (ISCIII), Ref. AC18/00057, associated with
REFERENCES

1. Morante-Palacios, O., Fendel, F., Ballestar, E. and Martínez-Cáceres, E.M. (2021) Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol., 42, 59–75.

2. Gallusso, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179, 1109–1118.

3. Collin, M. and Bigley, V. (2018) Human dendritic cell subsets: an update. Immunology, 154, 3–20.

4. Coillard, A. and Segura, E. (2019) In vivo differentiation of human monocytes. Front. Immunol., 10, 1907.

5. Rodríguez, R.M., Suarez-Alvarez, B., Lavin, J.L., Ascensión, A.M., González, M., Lozano, J.J., Rneros, A.B., Bulnes, P.D., Vidal-Castrejera, J.R., Huídobera, D. et al. (2019) Signal integration and transcriptional regulation of the inflammatory response mediated by the GM-/M-CSF signaling axis in human monocytes. Cell Rep., 29, 860–872.

6. de la Rica, L., Rodriguez-Uburea, J., Garcia, M., Islam, A.B.M.M.K., Urquiza, J.M., Hernando, H., Christensen, J., Helin, K., Gomez-Vaquero, C. and Ballestar, E. (2013) PU.1 target genes undergo TGF-β2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol., 14, R99.

7. Vento-Tormo, R., Company, C., Rodríguez-Uburea, J., de la Rica, L., Urquiza, J.M., Javierre, B.M., Sabarinathan, R., Luque, A., Esteller, M., Aran, J.M. et al. (2016) IL-4 orchestrates ST6-Mediated DNA demethylation leading to dendritic cell generation. Cell Biol., 17, 4.

8. Álvarez-Errico, D., Vento-Tormo, R., Sieweke, M. and Ballestar, E. (2015) Epigenetic control of myeloid cell differentiation, identity and function. Nat. Rev. Immunol., 15, 7–17.

9. Pacis, A., Mailhot-Leonard, F., Tailfleur, L., Randolph, H.E., Yotova, V., Dumaine, A., Grenier, J.-C. and Barreiro, L.B. (2019) Gene activation precedes DNA demethylation in response to infection in human dendritic cells. Proc. Natl. Acad. Sci. U.S.A., 116, 6938–6943.

10. Klug, M., Schmidhofer, S., Gebhard, C., Andreessen, R. and Rehli, M. (2013) 5-Hydroxymethylcytosine is an essential intermediate of active DNA demethylation processes in primary human monocytes. Genome Biol., 14, R46.

11. Mendes, K., Schmidhofer, S., Minderjahn, J., Glatz, D., Kiesewetter, C., Raithe, J., Wimmer, J., Gebhard, C. and Rehli, M. (2021) The epigenetic pioneer EGR2 initiates DNA demethylation in differentiating monocytes at both stable and transient binding sites. Nat. Commun., 12, 1556.

12. Morante-Palacios, O., Ciudad, L., Micheroli, R., de la Calle-Fabregat, C., Li,T., Barbisan, G., Houtman, M., Edalat,S.G., Frank-Bertoncelj, M., Osbelt, C. et al. (2022) Coordinated glucocorticoid receptor and MAFB action induces tolerogenesis and epigenome remodeling in dendritic cells. Nucleic Acids Res., 50, 108–126.

13. Catalá-Moll, F., Ferreté-Bonastre, A.G., Godoy-Tena, G., Morante-Palacios, O., Ciudad, L., Barberá, L., Fendel, F., Martínez-Cáceres, E.M., Rodríguez-Uburea, J., Li,T. et al. (2022) Vitamin d receptor, STAT3, and TET2 cooperate to establish tolerogenesis. Cell Rep., 38, 110244.

14. Levine, M., Yang, W., Padayatty,S.J. and Morrow, J. (2001) A new recommended dietary allowance of vitamin c for healthy young women. Proc. Natl. Acad. Sci. U.S.A., 98, 9842–9846.

15. Ang, A., Pullar,J.M., Currie,M.J. and Vissers,M.C.M. (2018) Vitamin c and immune cell function in inflammation and cancer. Biochem. Soc. Trans., 46, 1147–1152.

16. Jeong, Y.J., Kim,J.-H., Hong,J.-M., Kang,J.S., Kim,H.-R., Lee, W.J. and Hwang, Y. (2014) Vitamin c treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory t cell production capacity of these cells in vivo. Immunobiology, 219, 554–564.

17. Cimmino, L., Dolgalev, I., Wang, Y., Yoshimi, A., Martin,G.H., Wang, J., Ng,V., Xia, B., Witskowski,M.T., Mitchell-Flack, M. et al. (2017) Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell, 170, 1097–1095.

18. Magri, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S. et al. (2020) High-dose vitamin c enhances cancer immunotherapy. Sci. Transl. Med., 12, eaay8707.

19. Weulek, S.K., Cueto,F.J., Mujal,A.M., Melero, I., Krummel, M.F. and Sancho, D. (2020) Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol., 20, 7–24.

20. Schaadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F.O., Enk, A., Bröcker, E.-B., Grabbe, S., Rittgen, W., Edler, L., Sucker, A. et al. (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol., 17, 563–570.

21. Liu, L.M., Ashkan, K., Tran, D.D., Campian, J.L., Trusheim, J.E., Cobb, C.S., Heth, J.A., Salazc, M., Taylor, S., D’Andre,S.D. et al. (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med., 16, 142.

22. Godoy-Tena, G. and Ballestar, E. (2022) Epigenetics of dendritic cells in tumor immunology. Cancers (Basel), 14, 1179.

23. Morante-Palacios, O. and Ballestar, E. (2021) shinyEPCo: a graphical pipeline to analyze illumina DNA methylation arrays. Bioinformatics, 37, 257–259.

24. Aryee, M.J., Jaffe, A.E., Corradin-Braavo, H., Ladd-Acosta, C., Feinberg, A.P., Hansen, K.D. and Irizarry, R.A. (2014) Minfi: a flexible and comprehensive bioconductor package for the analysis of illumina DNA methylation microarrays. Bioinformatics, 30, 1363–1369.

25. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W. and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 447.

26. Touleimat, N. and Tost, J. (2012) Complete pipeline for infinium® human methylation 450k beadchip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics, 4, 325–341.

27. Triche, T.J., Jr., Weiserbein, D.J., Van Den Berg, D., Laird, P.W. and Siegmund, K.D. (2013) Low-level processing of illumina infinium DNA methylation beadarrays. Nucleic Acids Res., 41, e90.

28. Hinrichs, A.S., Karolchik, D., Baertsch, R., Barber, G.P., Bejerano, G., Clawson, H., Diekhans, M., Furey, T.S., Harte, R.A. and Hsu, F. et al. (2006) The UCSC genome browser database: update 2006. Nucleic Acids Res., 34, D490–D498.

29. Kim, D., Paggi, J.M., Park, C., Bennett, C. and Salzberg, S.L. (2019) Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol., 37, 907–915.

30. 1000 Genome Project Data Processing Subgroup, Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marsh, G., Abecasis, G. and Durbin, R. (2009) The sequence alignment/map format and SAMtools. Bioinformatics, 25, 2078–2079.

31. Liao, Y., Smyth, G.K. and Shi, W. (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30, 923–930.
32. Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, 15, 550.

33. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B. *et al.* (2012) Fiji: an open-source platform for biological-image analysis. *Nat. Methods*, 9, 676–682.

34. McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schara, B.T., Lowe, C.B., Wenger, A.M. and Bejerano, G. (2010) GREAT improves functional interpretation of cis-regulatory regions. *Nat. Biotechnol.*, 28, 495–501.

35. Yu, G., Wang, L.-G., Han, Y. and He, Q.-Y. (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. *Bioinformatics*, 31, 2761–2769.

36. Zerbino, D.R., Johnson, N., Jänteläinen, T., Wilder, S.P. and Flicek, P. (2014) Wiggles: parallel processing of large collections of genome-wide datasets for visualization and statistical analysis. *Bioinformatics*, 30, 1008–1009.

37. Fernández, J.M., de la Torre, V., Richardson, D., Royo, R., Puiggròs, M., Moncunill, V., Fragnioggianni, S., Clarke, L. and BLUEPRINT Consortium BLUEPRINT Consortium and Flicek, P. *et al.* (2016) The BLUEPRINT data analysis portal. *Cell Syst.*, 3, 491–495.

38. Johnson, J.S., Lucas, S.Y., Amon, L.M., Skelton, S., Nazito, R., Carbontett, S., Sather, D.N., Littman, D.R. and Aderem, A. (2018) Reshaping of the dendritic cell chromatin landscape and interferon pathways during HIV infection. *Cell Host Microbe*, 23, 366–381.

39. Lachmann, A., Xu, H., Krishnan, J., Berger, S.I., Mazloom, A.R. and Ma, ayan, A. (2010) ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. *Bioinformatics*, 26, 2438–2444.

40. Lee, J., Rhee, M.H., Kim, E. and Cho, J.Y. (2012) BAY 11–7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. *Mediators Inflamm.*, 2012, 416036.

41. de la Rica, L., Garcia-Gómez, A., Comet, N.R., Rodríguez-Ubcrea, J., Ciudad, L., Vento-Tormo, R., Company, C., Alvarez-Errico, D., Garcia, M., Gómez-Vaquero, C. *et al.* (2015) NF-κB-directed activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. *Genome Biol.*, 16, 2.

42. Wu, X. and Zhang, Y. (2017) TET-mediated active DNA demethylation: mechanism, function and beyond. *Nat. Rev. Genet.*, 18, 517–534.

43. Minor, E.A., Court, B.L., Young, J.I. and Wang, G. (2013) Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. *J. Biol. Chem.*, 288, 13669–13674.

44. Pacis, A., Taillieux, L., Morin, A.M., Lambourne, J., MacIsaac, J.L., Yotova, V., Dumaine, A., Danckaert, A., Luca, F., Grenier, J.-C. *et al.* (2015) Bacterial infection remodels the DNA methylation landscape of human dendritic cells. *Genome Res.*, 25, 1801–1811.

45. Blaschke, K., Ebata, K.T., Karimi, M.M., Zepeda-Martinez, J.A., Goyal, P., Mahapatra, S., Tan, A., Laird, D.J., Hirst, M., Rao, A. *et al.* (2013) Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature*, 500, 222–226.

46. Ravichandran, M., Jurkowski, R.Z. and Jurkowski, T.P. (2018) Target specificity of mammalian DNA methylation and demethylation machinery. *Org. Biomol. Chem.*, 16, 1419–1435.

47. Bauer, J., Namineni, S., Reisinger, F., Zölter, J., Yuan, D. and Heikenwälder, M. (2012) Lymphotixin, NF-C, and the dark side of cytokines. *Dig. Dis.*, 30, 453–468.

48. Browning, J.L., Miakowski, K., Sizing, I., Griffiths, D., Zafari, M., Benjamin, C.D., Meier, W. and Mackay, F. (1996) Signaling through the lymphotxin beta receptor induces the death of some adenocarcinoma tumor lines. *J. Exp. Med.*, 183, 867–878.

49. Lukashiev, M., LePage, D., Wilson, C., Bailly, V., Garber, E., Lukashin, A., Ngam-ek, A., Zeng, W., Allaire, N., Perrin, S. *et al.* (2006) Targeting the lymphotxin-beta receptor with agonist antibodies as a potential cancer therapy. *Cancer Res.*, 66, 9617–9624.

50. Cameron, E. and Pauling, L. (1976) Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. *Proc. Natl. Acad. Sci. U.S.A.*, 73, 3685–3689.

51. Cabanillas, F. (2010) Vitamin C and cancer: what can we conclude–1,609 patients and 33 years later? *P. R. Health Sci. J.*, 29, 215–217.

52. Das, A.B., Kakadia, P.M., Wojciech, D., Pemberton, L., Browett, P.J., Bohlander, S.K. and Vissers, M.C.M. (2019) Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. *Blood Cancer J.*, 9, 82.

53. Saisidharan Nair, V., Song, M.H. and Oh, K.I. (2016) Vitamin C facilitates demethylation of the foxp3 enhancer in a tet-dependent manner. *J. Immunol.*, 196, 2119–2131.

54. Kasahara, H., Kondo, T., Nakatsukasa, H., Chikuma, S., Ito, M., Ando, M., Kurebayashi, Y., Sekiya, T., Yamada, T., Okamoto, S. *et al.* (2017) Generation of allo-antigen-specific induced treg stabilized by vitamin C treatment and its application for prevention of acute graft versus host disease model. *Int. Immunol.*, 29, 457–469.

55. Iamsawat, S., Tian, L., Daenthanasanmak, A., Wu, Y., Nguyen, H.D., Bastian, D. and Yu, X.Z. (2019) Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. *Blood Adv.*, 3, 4137–4201.

56. Galati, D., Zanotta, S., Capitelli, L. and Bocchino, M. (2022) A bird’s eye view on the role of dendritic cells in SARS-CoV-2 infection: perspectives for immune-based vaccines. *Allergy*, 77, 100–110.

57. Garg, A.D., Coupe, P.G., Van den Eynde, B.J. and Agostinis, P. (2017) Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. *Trends Immunol.*, 38, 577–593.